Heidi Health vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Australian AI clinical documentation platform. Used by Monash Health (1.6M patients). $96.6M raised ($65M Series B at $465M valuation). Founded 2019, Melbourne.
About
Heidi Health was founded in 2019 in Melbourne, Australia by Dr. Thomas Kelly and Ryan Wright to eliminate the administrative burden of clinical documentation for healthcare providers. Clinicians spend 30–50% of working hours on documentation — typing notes, generating referral letters, completing forms — time that could otherwise go to patient care. Heidi built an ambient AI documentation platform that listens to patient consultations, transcribes in real time, and automatically generates structured clinical notes and referral letters tailored to each clinician's specialty.\n\nThe platform integrates with major EHR systems to push completed notes directly into patient charts, eliminating copy-paste friction. The AI engine supports general practice, specialist medicine, allied health, and nursing, and learns each clinician's personal documentation style over time to reduce editing effort. Heidi is deployed at Monash Health in Victoria, one of Australia's largest public health networks serving 1.6 million patients, as a flagship enterprise reference deployment.\n\nHeidi Health has raised $96.6 million in total funding, including a $65 million Series B at a $465 million valuation. The company is one of the fastest-growing clinical documentation AI platforms in Australia and is expanding internationally. As health systems globally address clinician burnout driven by documentation load, ambient AI documentation is emerging as a high-ROI technology investment, positioning Heidi Health alongside US-based competitors including Nuance DAX and Suki.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.